CUTANEOUS PTCL-NOS (CD8+ OR CD56+ AND CYTOTOXIC MARKER)

Clinical trials for CUTANEOUS PTCL-NOS (CD8+ OR CD56+ AND CYTOTOXIC MARKER) explained in plain language.

Never miss a new study

Get alerted when new CUTANEOUS PTCL-NOS (CD8+ OR CD56+ AND CYTOTOXIC MARKER) trials appear

Sign up with your email to follow new studies for CUTANEOUS PTCL-NOS (CD8+ OR CD56+ AND CYTOTOXIC MARKER), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New drug tested for Tough-to-Treat blood cancers

Disease control Recruiting now

This is the first study in people to test an experimental drug called DR-01 for adults with rare and aggressive blood cancers, including large granular lymphocytic leukemia (LGLL) and several types of cytotoxic lymphomas. The main goals are to find a safe dose and see if the drug…

Matched conditions: CUTANEOUS PTCL-NOS (CD8+ OR CD56+ AND CYTOTOXIC MARKER)

Phase: PHASE1, PHASE2 • Sponsor: Dren Bio • Aim: Disease control

Last updated Mar 11, 2026 14:54 UTC

CUTANEOUS PTCL-NOS (CD8+ OR CD56+ AND CYTOTOXIC MARKER)

Get alerted when new CUTANEOUS PTCL-NOS (CD8+ OR CD56+ AND CYTOTOXIC MARKER) trials appear

New drug tested for Tough-to-Treat blood cancers